SLC5A2 and type 2 diabetes mellitus: The dual benefit of improving both liver and cardiovascular outcomes positions SGLT2 inhibitors as potentially transformative therapies for MASLD patients, particularly those with coexisting T2DM and cardiovascular risk factors.